| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $32,200,902 | 43 | 100 |
| McCain Tracey L | EVP AND CHIEF LEGAL OFFICER | 0 | $0 | 1 | $467,266 | $-467,266 |
| Carter Percy H. | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 2 | $653,497 | $-653,497 |
| Landsittel Michael | CHIEF FINANCIAL OFFICER | 0 | $0 | 2 | $889,088 | $-889,088 |
| Hewes L. Becker | CHIEF MEDICAL OFFICER | 0 | $0 | 2 | $890,639 | $-890,639 |
| Namouni Fouad | PRESIDENT, R & D | 0 | $0 | 2 | $900,723 | $-900,723 |
| Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 0 | $0 | 5 | $1.09M | $-1.09M |
| COATS LONNEL | director | 0 | $0 | 2 | $1.87M | $-1.87M |
| Haviland Kate | CHIEF EXECUTIVE OFFICER | 0 | $0 | 4 | $2.04M | $-2.04M |
| Rossi Christina | CHIEF OPERATING OFFICER | 0 | $0 | 8 | $2.15M | $-2.15M |
| Lee Philina | CHIEF COMMERCIAL OFFICER | 0 | $0 | 2 | $4.24M | $-4.24M |
| Albers Jeffrey W. | director | 0 | $0 | 8 | $7.39M | $-7.39M |
| Durso-Bumpus Debra | CHIEF PEOPLE OFFICER | 0 | $0 | 5 | $9.62M | $-9.62M |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Blueprint Medicines Corporation have bought $0 and sold $32.2M worth of Blueprint Medicines Corporation stock.
On average, over the past 5 years, insiders at Blueprint Medicines Corporation have bought $174,552 and sold $22.17M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100 shares for transaction amount of $48,378 was made by Haviland Kate (CHIEF EXECUTIVE OFFICER) on 2022‑11‑03.
| 2025-06-03 | Sale | Carter Percy H. | CHIEF SCIENTIFIC OFFICER | 2,659 0.0041% | $127.88 | $340,033 | +0.17% | |
| 2025-05-27 | Sale | Albers Jeffrey W. | director | 5,000 0.0078% | $101.14 | $505,692 | +25.58% | |
| 2025-05-19 | Sale | Rossi Christina | CHIEF OPERATING OFFICER | 2,274 0.0035% | $100.51 | $228,557 | +26.90% | |
| 2025-05-05 | Sale | Rossi Christina | CHIEF OPERATING OFFICER | 2,274 0.0035% | $101.75 | $231,386 | +0.45% | |
| 2025-05-05 | Sale | Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 2,752 0.0043% | $103.13 | $283,819 | +0.45% | |
| 2025-04-01 | Sale | Haviland Kate | CHIEF EXECUTIVE OFFICER | 2,498 0.0039% | $86.65 | $216,461 | +15.45% | |
| 2025-03-24 | Sale | Rossi Christina | CHIEF OPERATING OFFICER | 2,274 0.0035% | $95.02 | $216,075 | +3.66% | |
| 2025-03-12 | Sale | Albers Jeffrey W. | director | 7,500 0.0114% | $87.80 | $658,500 | +2.85% | |
| 2025-03-06 | Sale | Hewes L. Becker | CHIEF MEDICAL OFFICER | 5,232 0.0081% | $87.69 | $458,804 | +2.46% | |
| 2025-03-05 | Sale | Haviland Kate | CHIEF EXECUTIVE OFFICER | 16,151 0.0249% | $88.80 | $1.43M | +0.77% | |
| 2025-03-05 | Sale | Albers Jeffrey W. | director | 5,766 0.0089% | $88.80 | $512,021 | +0.77% | |
| 2025-03-05 | Sale | Namouni Fouad | PRESIDENT, R & D | 6,489 0.01% | $88.80 | $576,223 | +0.77% | |
| 2025-03-05 | Sale | Landsittel Michael | CHIEF FINANCIAL OFFICER | 5,284 0.0082% | $88.80 | $469,219 | +0.77% | |
| 2025-03-05 | Sale | Rossi Christina | CHIEF OPERATING OFFICER | 6,495 0.01% | $88.80 | $576,756 | +0.77% | |
| 2025-03-05 | Sale | McCain Tracey L | EVP AND CHIEF LEGAL OFFICER | 5,262 0.0081% | $88.80 | $467,266 | +0.77% | |
| 2025-03-05 | Sale | Carter Percy H. | CHIEF SCIENTIFIC OFFICER | 3,530 0.0055% | $88.80 | $313,464 | +0.77% | |
| 2025-03-05 | Sale | Durso-Bumpus Debra | CHIEF PEOPLE OFFICER | 5,157 0.008% | $88.80 | $457,942 | +0.77% | |
| 2025-03-05 | Sale | Lee Philina | CHIEF COMMERCIAL OFFICER | 3,733 0.0058% | $88.80 | $331,490 | +0.77% | |
| 2025-03-05 | Sale | Hewes L. Becker | CHIEF MEDICAL OFFICER | 4,863 0.0075% | $88.80 | $431,834 | +0.77% | |
| 2025-03-05 | Sale | Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 1,326 0.002% | $88.80 | $117,749 | +0.77% |
| Haviland Kate | CHIEF EXECUTIVE OFFICER | 165929 0.2569% | $21.23M | 1 | 30 | +11.1% |
| Albers Jeffrey W. | director | 146630 0.227% | $18.76M | 0 | 61 | |
| Namouni Fouad | PRESIDENT, R & D | 75781 0.1173% | $9.7M | 0 | 8 | |
| Landsittel Michael | CHIEF FINANCIAL OFFICER | 72924 0.1129% | $9.33M | 0 | 11 | |
| McCain Tracey L | EVP AND CHIEF LEGAL OFFICER | 66583 0.1031% | $8.52M | 0 | 10 | |
| Rossi Christina | CHIEF OPERATING OFFICER | 64718 0.1002% | $8.28M | 0 | 16 | |
| Carter Percy H. | CHIEF SCIENTIFIC OFFICER | 54206 0.0839% | $6.94M | 0 | 8 | |
| Durso-Bumpus Debra | CHIEF PEOPLE OFFICER | 49606 0.0768% | $6.35M | 0 | 16 | |
| Lee Philina | CHIEF COMMERCIAL OFFICER | 41996 0.065% | $5.37M | 0 | 5 | |
| Hewes L. Becker | CHIEF MEDICAL OFFICER | 30419 0.0471% | $3.89M | 0 | 16 | |
| Hurley Ariel | PRINCIPAL ACCOUNTING OFFICER | 16944 0.0262% | $2.17M | 0 | 43 | |
| COATS LONNEL | director | 2242 0.0035% | $286,886.32 | 0 | 3 | |
| Third Rock Ventures II, L.P. | 10 percent owner | 4453753 6.8963% | $569.9M | 0 | 1 | |
| FMR LLC | 264898 0.4102% | $33.9M | 1 | 9 | +9.46% | |
| LYNCH DANIEL | director | 174342 0.27% | $22.31M | 0 | 10 | |
| LEVIN MARK J | 10 percent owner | 111244 0.1723% | $14.23M | 0 | 1 | |
| Borisy Alexis | director | 60906 0.0943% | $7.79M | 0 | 7 | |
| Lengauer Christoph | Chief Scientific Officer | 56657 0.0877% | $7.25M | 0 | 8 | |
| Lydon Nicholas | director | 37425 0.0579% | $4.79M | 0 | 11 | |
| Murray Christopher K. | CHIEF TECHNICAL OPERATIONS | 33853 0.0524% | $4.33M | 0 | 11 | |
| Boral Anthony L. | Chief Medical Officer | 28147 0.0436% | $3.6M | 0 | 11 | |
| Dorsch Marion | Chief Scientific Officer | 15250 0.0236% | $1.95M | 0 | 14 | |
| Goldberg Mark Alan | 10812 0.0167% | $1.38M | 1 | 6 | <0.0001% | |
| Demetri George | 5822 0.009% | $744,983.12 | 1 | 9 | <0.0001% | |
| Rowland Charles A Jr | director | 3562 0.0055% | $455,793.52 | 0 | 4 | |
| STARR KEVIN P | 10 percent owner | 0 0% | $0 | 0 | 1 |
$961,890,236 | 276 | 22.46% | $13.11B | |
$159,914,414 | 243 | 18.52% | $7.43B | |
$211,610,344 | 91 | 38.45% | $6.56B | |
$2,765,836 | 72 | 20.00% | $10.78B | |
$108,876,545 | 67 | 72.81% | $6.65B | |
$11,789,714 | 49 | 14.35% | $17.98B | |
$323,520,369 | 46 | 31.46% | $40.16B | |
$88,307,390 | 38 | -1.70% | $6.57B | |
$13,655,378 | 35 | 17.13% | $12.78B | |
$15,169,821 | 35 | 70.30% | $11.34B | |
$415,105,240 | 19 | -14.04% | $7.55B | |
$83,065,496 | 16 | 9.40% | $7.56B | |
$152,272,932 | 16 | -10.78% | $19.59B | |
$627,701,115 | 15 | 145.68% | $14.59B | |
$948,235 | 8 | 15.55% | $7.92B | |
$40,276,273 | 4 | 34.57% | $7.7B | |
Blueprint Medicines Corporation (BPMC) | $4,849,105 | 4 | 2.71% | $8.26B |
$6,678,053 | 3 | 30.56% | $7.84B | |
$999,989 | 1 | 262.16% | $10.31B |
| Increased Positions | 203 | +53.99% | 11M | +16.45% |
| Decreased Positions | 167 | -44.41% | 8M | -11.68% |
| New Positions | 66 | New | 3M | New |
| Sold Out Positions | 54 | Sold Out | 1M | Sold Out |
| Total Postitions | 412 | +9.57% | 70M | +4.77% |
| Vanguard Group Inc | $708,924.00 | 10.42% | 6.77M | +91,450 | +1.37% | 2024-12-31 |
| Blackrock, Inc. | $702,208.00 | 10.32% | 6.71M | -158,619 | -2.31% | 2025-03-31 |
| Price T Rowe Associates Inc /Md/ | $594,260.00 | 8.74% | 5.68M | +291,822 | +5.42% | 2024-12-31 |
| Wellington Management Group Llp | $448,002.00 | 6.59% | 4.28M | +316,754 | +7.99% | 2024-12-31 |
| State Street Corp | $261,622.00 | 3.85% | 2.5M | -265,495 | -9.6% | 2024-12-31 |
| Fmr Llc | $235,197.00 | 3.46% | 2.25M | -2M | -50.24% | 2024-12-31 |
| William Blair Investment Management, Llc | $203,493.00 | 2.99% | 1.94M | +269,896 | +16.11% | 2024-12-31 |
| Geode Capital Management, Llc | $155,924.00 | 2.29% | 1.49M | +9,914 | +0.67% | 2024-12-31 |
| Macquarie Group Ltd | $131,739.00 | 1.94% | 1.26M | -4,685 | -0.37% | 2024-12-31 |
| Avoro Capital Advisors Llc | $123,998.00 | 1.82% | 1.19M | +1M | New | 2024-12-31 |